Benign Prostate Hyperplasia Clinical Trial
— TURPVerified date | April 2016 |
Source | Shiraz University of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | Iran: Ministry of Health |
Study type | Interventional |
Preoperative use of finastride will decrease the amount of perioperative blood loss during
and after TURP
The effect of finastride on decreasing the amount of perioperative blood loss during and
after TURP is dose dependent
Finastride will decrease microvascular density in prostate tissue and this effect is dose
dependent
Status | Completed |
Enrollment | 60 |
Est. completion date | May 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Patients with BPH that require TURP Exclusion Criteria: - Previous prostate surgery - Prostate Cancer - Coagulopathy - The use of NSAIDs, Anticoagulants, Antiplatelet drugs - CRF/ESRD |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Faghihi Hospital | Shiraz | Fars |
Lead Sponsor | Collaborator |
---|---|
Shiraz University of Medical Sciences |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Perioperative Hb Drop | 24 hours after surgery | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01942551 -
Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride
|
Phase 1 | |
Completed |
NCT01436877 -
Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia
|
N/A | |
Completed |
NCT02822924 -
Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT02390882 -
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH
|
Phase 3 | |
Completed |
NCT02839122 -
A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects
|
Phase 1 | |
Not yet recruiting |
NCT01861041 -
Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy.
|
Phase 4 | |
Completed |
NCT02332538 -
HoLEP vs. Greenlight 532nm-laser PVEP vs. Bipolar TURP in Management of Moderate/ Large BPH
|
N/A | |
Completed |
NCT01835860 -
Prostatic Artery Embolization for Benign Prostatic Hyperplasia
|
Phase 2/Phase 3 | |
Completed |
NCT01665586 -
Effective Dose of Dexmedetomidine for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia With or Without Fentanyl by Age Groups: Randomized Comparative Study
|
N/A | |
Completed |
NCT02038868 -
A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia
|
Phase 2 | |
Completed |
NCT02506465 -
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
|
N/A | |
Completed |
NCT01675895 -
Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration
|
Phase 4 | |
Completed |
NCT02483819 -
Changes of the Hemodynamic Profiles on Bio Reactance Technique During TURP in Elderly Patients
|
N/A | |
Recruiting |
NCT02827578 -
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
|
Phase 3 | |
Completed |
NCT02352311 -
Safety and Pharmacokinetic Characteristics of DKF-313
|
Phase 1 | |
Completed |
NCT01494337 -
Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP)
|
Phase 4 | |
Completed |
NCT01952912 -
Plasmakinetic Enucleation of the Prostate and Open Prostatectomy to Treat Large Prostates
|
N/A | |
Active, not recruiting |
NCT01736033 -
Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
|
Phase 4 | |
Recruiting |
NCT02021032 -
Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
Phase 4 | |
Completed |
NCT00861588 -
Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia
|
N/A |